Two additional Spanish centers announce adoption of the Xoft System, totaling seven installations across four major regions in Spain

Internationally-recognized institutions strengthen portfolio of comprehensive cancer care solutions with iCAD’s state-of-the-art electronic brachytherapy technology

Nashua, N.H. – Apri... Continue reading

Company’s Latest, Deep-Learning, Cancer Detection Software Solution Recently Launched in U.S.

Nashua, NH – (April 4, 2019) – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will present its latest artificial intelligence software so... Continue reading

Appointment establishes executive infrastructure to enhance strategic and operational momentum and capitalize on significant growth opportunities

Announcement follows pivotal FDA clearance and successful U.S. commercial launch of ProFound AI™ for digital breast tomosynthesis along with strong financial results reported on recent fourth quarter 2018 earnings call

Expands upon Ms. Stevens’ prior commercialization & strategy acumen an... Continue reading

Company achieved key milestone in fourth quarter with FDA clearance and subsequent U.S. commercial launch of ProFound AI™ for digital breast tomosynthesis

Conference call today at 4:30 p.m. ET

NASHUA, N.H. (March 18, 2019) – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection a... Continue reading

NASHUA, N.H., (March 14, 2019) – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today reported strong adoption of its latest deep-learning, cancer detection software solution for digital breast tomosynthesis (DBT), ProFound AI™. The powerful solution built on artificial intelligence (AI) delivers critical benefits to radiologists, their facilities and patients in identifying cancer earlier.

Continue reading

NASHUA, N.H. -- March 14, 2019 –  iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that Michael Klein, Chief Executive Officer, and Stacey Stevens, Chief Strategy & Commercial Officer, will be meeting with investors in a one-on-one format at the 31st Annual ROTH Conference, being held March 17-19 in Laguna Niguel, California. 

About iCAD, Inc.

Headquartered in Nashua, NH, iCAD i... Continue reading

NASHUA, N.H. (March 13, 2019) –  iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will release financial results for the fourth quarter and fiscal year ended December 31, 2018, after the close of the market and host a conference call at 4:30 pm Eastern Time on Monday, March 18.

Monday, March 18, 2019, at 4:30 PM ET

Domestic:          &nbs... Continue reading

Proposed Collaboration would support iCAD’s leadership position in providing AI-based solutions that advance risk assessment for breast cancer

VIENNA, Austr... Continue reading

By Jeffrey Hoffmeister, MD, VP, Medical Director at iCAD, a global leader in medical technology providing innovative cancer detection and therapy solutions

Artificial intelligence (AI) is revolutionizing the healthcare industry, with potential to make dramatic improvements in clinical care and provider efficiency. By 2021, Accenture estimates the health AI market will reach .6 billion as the industry seeks to improve cost, quality and access to care.

Some of the most dr... Continue reading

Currently pending CE Mark, ProFound AI technology for 2D mammography will also be previewed

Nashua, NH – (Feb. 21, 2019) – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will present its latest artificial intelligence software solution for digital breast tomosynthesis (DBT), ProFound AI™, in the... Continue reading

Prospective trial shows that intraoperative radiation therapy (IORT) is a clinically effective, faster and easier alternative to whole breast radiation therapy following breast-conserving surgery for selected low-risk patients at a median follow-up of 36 months

NASHUA, N.H., (January 7, 2019) – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the results of a long-term study conducted at Hoag Memorial Hospital Presbyterian with the Xoft®... Continue reading

RSNA 2018 is a wrap, but the buzz continues, and we want to thank everyone that visited with iCAD during the show that had the opportunity to experience our ProFound AI solution for breast tomosynthesis and those we have met with since the show closed. 

As you can imagine, lots has changed in the field of radiology over the past several decades, which made the meeting especially interesting and perhaps one of the best yet.   Each year, thousands of radiologists, health imaging specialists... Continue reading

NASHUA, N.H., (December 27, 2018) – iCAD, Inc. (NASDAQ: ICAD), a global medical technology company providing innovative cancer detection and therapy solutions, today announced that Richard Christopher, Executive Vice President, Chief Financial Officer, is resigning from the Company to pursue another career opportunity, effective January 11, 2019. Mr. Christopher’s resignation is not the result of any dispute or disagreement with iCAD or any matter relating to the Company’s accounting practices or financial statements. iCAD’s Board of Directors has appro... Continue reading

Added Funds to support global commercialization of cancer detection capability and cancer therapy technology    

NASHUA, N.H., December 20, 2018  -- iCAD, Inc. (NASDAQ: ICAD), a  global medical technology company providing innovative cancer detection and therapy solutions, today announced that it has entered into definitive agreements to sell unsecured subordinated convertible debentures, due three years following issuance, to... Continue reading

High-performance, cancer detection technology built on artificial intelligence now available to healthcare facilities in the U.S.

New U.S. clearance based on clinical results demonstrating unprecedented improvements in clinical performance and workflow efficiency

Continue reading

Clinical results presented demonstrate outstanding outcomes with world-class artificial intelligence technology

NASHUA, N.H. and CHICAGO (Booth #3911 and #8161) – (Nov. 26, 2018) – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the global brand identity for its latest artificial intelligence software so... Continue reading

Company announces board and leadership changes

Conference call today at 4:30 p.m. ET

NASHUA, N.H. (November 13, 2018) – iCAD, Inc. (NASDAQ: ICAD), a global medical technology company providing innovative cancer detection and therapy solutions, today reported financial results for the three and nine months... Continue reading

Michael Klein, Chairman of the Board, to serve as Executive Chairman and Interim CEO

NASHUA, N.H., (November 9, 2018) – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that Ken Ferry has retired from his position as Chief Executive Officer (CEO) and stepped down as a Director of the Company, effective immediately. Michael Klein, Chairman of iCAD’s Board, will serve as Executive Chairman and... Continue reading

NASHUA, N.H. (November 6, 2018) –  iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will release financial results for the third quarter and nine months ended September 30, 2018 after the close of the market and host a conference call at 4:30pm Eastern Time on Tuesday, November 13th.

Tuesday, November 13th @ 4:30 pm Eastern Time

Domestic:        ... Continue reading

Prominent medical center is first in the United States to expand breast health offerings with iCAD’s PowerLook Tomo Detection solution and Xoft System

NASHUA, N.H., and Macon, GA, (October 30, 2018) – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that its complete suite of leading-edge breast health innovations including PowerLook® Tomo Detection, a radiology wor... Continue reading